Amgen (AMGN) and AstraZeneca (AZN) report that their phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Primary endpoints were patients achieving at least a 75% improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index (PASI 75), and patients achieving clear or almost clear skin at week 12 according to the static Physician Global Assessment.
Shares of both companies are flat in after-hours trade.
Latest posts by Anne-Marie Jackson (see all)
- Humpback Whales May Face A Fair Number Of Boat Collisions - Apr 25, 2017
- Elon Musk Confirmed His Dreams And Position In Neuralink - Apr 23, 2017
- Toyota Is Launching A Rental Service For Its Robotic Leg Brace - Apr 17, 2017